Polypeptide Procalcitonin Drives Cardiac & Microvascular Injury in Sepsis, Shock, and Cardiac Arrest
Background
High mortality in conditions like sepsis, acute myocardial infarction (AMI), cardiac arrest (CA), and Takotsubo syndrome (TS) remains a critical challenge in modern medicine. Current treatments often fall short in addressing the systemic inflammatory responses and multi-organ dysfunction that characterize these severe conditions. Polypeptide procalcitonin, a precursor to the hormone calcitonin, is increasingly recognized as a key mediator in inflammatory states. Understanding its precise role and mechanisms in cardiac and microvascular injury could unlock novel therapeutic strategies to improve patient outcomes.
Study Design
This comprehensive review synthesized existing literature to elucidate the multifaceted role of polypeptide procalcitonin in critical cardiac conditions and systemic stress. Researchers analyzed studies detailing its synthesis, secretion, and mechanistic involvement in septic shock (SS), cardiogenic shock (CS), cardiac arrest, and Takotsubo syndrome. The review focused on identifying specific pathways, such as toll-like receptor-4 (TLR-4) activation and calcitonin gene-related peptide receptor (CGRP) signaling, to clarify procalcitonin's pathogenic contributions to cardiac and microvascular injury.
Results
Circulating procalcitonin levels significantly increase in septic shock, cardiogenic shock, cardiac arrest, and Takotsubo syndrome. Lipopolysaccharide stimulates procalcitonin production via toll-like receptor-4 (TLR-4) activation and the nuclear factor of κ light polypeptide gene enhancer in B-cells (NF-κB) transcription factor. Procalcitonin activates the calcitonin gene-related peptide receptor in endothelial cells, alongside an unidentified receptor, leading to detrimental effects. > Procalcitonin causes lung microvessel injury, apoptosis, and pyroptosis of endothelial cells, directly contributing to organ damage.In animal models, procalcitonin antibodies increased survival in sepsis, while exogenous procalcitonin exacerbated sepsis. Elevated circulating procalcitonin levels are associated with acute heart failure and predict mortality after septic shock, cardiogenic shock, and cardiac arrest. However, in patients with AMI, increased procalcitonin was linked to acute heart failure but not microvascular injury or intramyocardial hemorrhage.
Key Findings
- Circulating procalcitonin levels are significantly elevated in septic shock, cardiogenic shock, cardiac arrest, and Takotsubo syndrome.
- Procalcitonin production is stimulated by
lipopolysaccharideviaTLR-4andNF-κBactivation. - Procalcitonin activates the
calcitonin gene-related peptide receptorin endothelial cells, causing lung microvessel injury, apoptosis, and pyroptosis. - Procalcitonin antibodies improve survival in animal models of sepsis, while exogenous procalcitonin exacerbates it.
- Elevated procalcitonin levels predict mortality after septic shock, cardiogenic shock, and cardiac arrest.
Why It Matters
This review highlights procalcitonin as a central player in the pathogenesis of severe cardiac and inflammatory conditions, offering a clear therapeutic target. For clinicians and biohackers, this suggests that monitoring procalcitonin levels could provide crucial prognostic information and guide treatment decisions in sepsis, shock, and post-cardiac arrest care. The identification of the calcitonin gene-related peptide receptor as a key mediator opens avenues for developing novel drugs. CGRP receptor antagonists and procalcitonin monoclonal antibodies could become foundational treatments for septic shock, cardiogenic shock, Takotsubo syndrome, and preventing death after cardiac arrest, moving beyond current supportive care to targeted intervention. This research underscores the potential for precision medicine approaches in critical care.
procalcitonin
sepsis
cardiogenic-shock
cardiac-arrest
takotsubo-syndrome
inflammation